HUTCHMED (NASDAQ:HCM) PT Raised to $17.00 at The Goldman Sachs Group

HUTCHMED (NASDAQ:HCM) had its price target raised by The Goldman Sachs Group from $15.00 to $17.00 in a report released on Friday, Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

Several other analysts also recently weighed in on HCM. Citigroup assumed coverage on shares of HUTCHMED in a research report on Wednesday, August 2nd. They set a buy rating on the stock. StockNews.com assumed coverage on shares of HUTCHMED in a research note on Thursday, October 5th. They set a hold rating for the company. Finally, Cantor Fitzgerald restated an overweight rating and set a $50.00 price objective on shares of HUTCHMED in a research note on Tuesday, September 5th.

HUTCHMED Trading Up 5.1 %

NASDAQ HCM opened at $19.02 on Friday. The company’s 50-day simple moving average is $16.97 and its two-hundred day simple moving average is $14.65. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.20 and a quick ratio of 3.04. HUTCHMED has a one year low of $9.48 and a one year high of $21.28.

Hedge Funds Weigh In On HUTCHMED

Several large investors have recently made changes to their positions in the company. XY Capital Ltd lifted its holdings in HUTCHMED by 5.8% during the first quarter. XY Capital Ltd now owns 11,550 shares of the company’s stock valued at $150,000 after purchasing an additional 637 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in HUTCHMED by 4.5% during the second quarter. Cubist Systematic Strategies LLC now owns 22,273 shares of the company’s stock valued at $282,000 after purchasing an additional 950 shares in the last quarter. UBS Group AG lifted its holdings in HUTCHMED by 2.5% during the first quarter. UBS Group AG now owns 57,848 shares of the company’s stock valued at $753,000 after purchasing an additional 1,401 shares in the last quarter. Janney Capital Management LLC lifted its holdings in HUTCHMED by 12.0% during the first quarter. Janney Capital Management LLC now owns 16,824 shares of the company’s stock valued at $219,000 after purchasing an additional 1,797 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in HUTCHMED by 26.2% during the first quarter. Tower Research Capital LLC TRC now owns 8,931 shares of the company’s stock valued at $116,000 after purchasing an additional 1,855 shares in the last quarter. 14.13% of the stock is currently owned by institutional investors and hedge funds.

About HUTCHMED

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.